COMMON INHERITED METABOLIC CONDITIONS IN SOUTH AFRICA DIAGNOSING RARE DISEASE IN GENETICALLY UNIQUE AND UNDERSTUDIED POPULATION GROUPS

Similar documents
Investigation of metabolic encephalopathy

Further expansion of the neonatal screening panel in the Netherlands

Routine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015

For Your Baby s Health Department of Health

Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy

Newborn Screening: Focus on Treatment

Whole exome sequencing as a first line test: Is there even a role for metabolic biochemists in the future?

Positive Newborn Screens: What do you do next?

Slide 1: Newborn Bloodspot Screening for Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

The laboratory investigation of lactic acidaemia. J Bonham/T Laing

Diagnose a broad range of metabolic disorders with a single test, Global MAPS

Current Management and Future Developments in Metabolic Disease

A Guide for Prenatal Educators

Newborn Screening & Methods for Diagnosing Inborn Errors of Metabolism

NEWBORN METABOLIC SCREEN, MINNESOTA

When users open the application interface, the starting page presents a disclaimer. Upon agreeing to the

[R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS DEPARTMENT OF HEALTH. February October October 1992 (E) September 1995

HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up

Title: Assessing Recommendations Related To Timeliness of Newborn Screening

TIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN

The Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State. Saving lives with a simple blood spot

Inborn Errors of Metabolism Clinical Approach to Diagnosis and Treatment

INBORN ERRORS OF METABOLISM (IEM) IAP UG Teaching slides

Most common is the congenital adrenogenital syndrome (AGS) or congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.

MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES

CSF Investigations in patients with seizures. Dr Simon Olpin Sheffield Children s Hospital

NEWBORN SCREENING. in Massachusetts: Answers for You and Your Baby. University of Massachusetts Medical School

Acylcarnitines And Inherited Metabolic Disease. David Hardy

Inborn Errors of Metabolism From Neonatal Screening to Metabolic Pathways

BROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING.

Newborn Screening in Washington State Saving lives with a simple blood spot

Post mortem investigation of Inherited Metabolic Disease - the last opportunity for a diagnosis -

Newborn Bloodspot Screening (NBS) Training for Health Visitors. December 2017

NEWBORN SCREENING. health.mo.gov/newbornscreening MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES

Newborn Bloodspot Screening Information for parents

Newborn Screening in Manitoba. Information for Health Care Providers

Inherited Metabolic Disease

Newborn Bloodspot Screening Information for parents

Paediatric Inherited Metabolic Medicine

A. disorders of amino acid metabolism classical phenylketonuria and hyperphenylalaninemia

The spectrum and outcome of the. neonates with inborn errors of. metabolism at a tertiary care hospital

Newborn bloodspot testing

Metabolic Changes in ASD. Norma J. Arciniegas, MD Simón E. Carlo, MD Instituto Filius

NEWBORN SCREENING. in Massachusetts: Information for You and Your Baby. University of Massachusetts Medical School

(f) "Birthing center" means any facility that is licensed by the Georgia Department of Community Health as a birthing center;

Newborn Metabolic Screening Programme Annual Report

Inborn Errors of Metabolism

Neonatal Biochemistry Investigation for Inherited Metabolic Disorders (IMDs)

D evelopmental disabilities occur in approximately

Newborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis)

CHRONIC MYELOGENOUS LEUKEMIA

Metabolic Disorders. Chapter Thomson - Wadsworth

Acylcarnitine measurement in blood spots: methodological aspects, problems and pitfalls with reference to the ERNDIM QA scheme

Beyond the case for NBS in South Africa. Chris Vorster 28/05/2016

CLINICAL AND HUMAN TESTING

Subject: Enteral Formulas

Newborn Screening: Blood Spot Disorders

All diseases on Foresight

Understanding metabolic disease

Suspected Metabolic Disease in the Newborn Period Acute Management "What do I do?" Barbara Marriage, PhD RD Abbott Nutrition

For the Ongoing Management of Babies under 1 year old.

Inborn Errors of Metabolism. Metabolic Pathway. Digestion and Fasting. How is Expanded Newborn Screening Different? MS/MS. The body is a factory.

CLINICAL SIGNS SUGGESTIVE OF A NEUROMETABOLIC DISEASE. Bwee Tien Poll-The Amsterdam UMC The Netherlands

Training Syllabus CLINICAL SYLLABUS

Lauren E. Cipriano, BSc, BA, 1 C. Anthony Rupar, PhD, 2 Gregory S. Zaric, PhD 1. Introduction

Metabolic Disorders Screened Overseas but not Screened in Australia Condition Features Inherited Diagnosis Treatment Newborn Screen

Newborn Metabolic Screening Programme. Annual Report

Inborn Errors of Metabolism (IEM)

A rough guide to Acylcarnitines

Utility of Microarrays in Molecular Genetics

Clinical Management of Organic Acidemias and OAA Natural History Registry. Kim Chapman MD PhD Children s National Rare Disease Institute

Introduction to Organic Acidemias. Hilary Vernon, MD PhD Assistant Professor of Genetic Medicine Johns Hopkins University 7.25.

Neonatal Guidelines. Chapter 10: Metabolic V Date Revised : January 2017 Ratified 6 th February Date for Review: 1 st of March 2021

Pilot Study of Newborn Screening (NBS) for Inborn Errors of Metabolism (IEM) in Collaboration with Department of Health and Hospital Authority

inborn errors of metabolism biochemical basis

2015 Annual Report for New Mexico s Newborn Screening (NBS) Program

Background information on Newborn Screening

Newborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet

Newborn Metabolic Screening Programme

The Israeli population carrier screening program. Joël Zlotogora MD, PhD Hadassah medical school Hebrew University Jerusalem

Paediatric Clinical Chemistry

Organic acidaemias (OAs) & Urea cycle disorders (UCDs) PRESENTATION & MANAGEMENT

Newborn screening for additional metabolic diseases using second-tier strategies Juergen G. Okun, PhD

GUIDE TO NEWBORN SCREENING PROGRAMME

Prevalence of selected disorders of inborn errors of metabolism in suspected cases at a Tertiary Care Hospital in Karachi

National Metabolic Biochemistry Network Best Practice Guidelines. The Biochemical Investigation of Fits and Seizures for Inherited Metabolic Disorders

USERS HANDBOOK Version 4.0

Detection of inborn errors of metabolism in the newborn

BIOCHEMICAL GENETICS UNIT METABOLIC ASSAYS

BIOCHEMICAL GENETICS UNIT METABOLIC ASSAYS

Expanded newborn screening

Proficiency Testing Centre Basel Annual Report 2007

UK NATIONAL METABOLIC BIOCHEMISTRY NETWORK GUIDELINES FOR THE INVESTIGATION OF HYPERAMMONAEMIA

Summary. Syndromic versus Etiologic. Definitions. Why does it matter? ASD=autism

BIOCHEMICAL GENETICS UNIT METABOLIC ASSAYS

Foresight Carrier Screen

Doenças Hereditárias do Metabolismo: de Garrod às Ciências Ómicas

Medical Foods for Inborn Errors of Metabolism

Chapter 26. Outline. Nitrogen. Nitrogen and Amino Acid Metabolism. BCH 4054 Spring 2001 Chapter 26 Lecture Notes. Slide 1. Slide 2

Transcription:

COMMON INHERITED METABOLIC CONDITIONS IN SOUTH AFRICA DIAGNOSING RARE DISEASE IN GENETICALLY UNIQUE AND UNDERSTUDIED POPULATION GROUPS S MELDAU, G VAN DER WATT INHERITED METABOLIC DISEASES GROUP UCT / NHLS

NHLS/UCT INHERITED METABOLIC DISEASES GROUP Clinical diagnosis Clinicians Biochemistry - amino acids, organic acids, carnitines, VLCFAs etc Red Cross Hospital - Chemistry Tissue Culture + specific enzyme assay Metabolic lab UCT Genetic analysis IMD molecular lab - GSH

OBJECTIVES TO PRESENT COMBINED RARE DISEASE DATA FROM THE NATIONAL HEALTH LABORATORY SERVICES (NHLS) INHERITED METABOLIC DISEASE (IMD) LABORATORIES AT RXH AND GSH OVER THE PAST 0 YEARS METHODS DATA FROM IMD CASES WITH CONFIRMED DIAGNOSES WERE RETRIEVED FROM EXISTING DATABASES AT THE TWO REFERRAL CENTRES. ALL IDENTIFIABLE PATIENT INFO HAVE BEEN REMOVED.

GALACTOSAEMIA (N=45) 5 38 p.s35l/p.s35l p.q88r/p.s35l p.s35l/?

GLUTARIC ACIDURIA TYPE (N=38) 4 9 GCDH: p.a93t/p.a93t GCDH: p.a93t/? GCDH: p.a93t/p.his96pro(vus) GCDH: p.a93t/p.r40w GCDH: p.glu59pro/p.glu59pro GCDH: p.r355c/p.r383c

CYSTINOSIS (N=~3) 9 CTNS:c.97-G>A/c.97-G>A CTNS:c.97-G>A/c.809C>T CTNS:c.97-G>A/c.8_delGACT CTNS:c.97-G>A/c.4C>T

MPV7 NEUROHEPATOPATHY (See Poster #P3) 5 MPV7:p.Q36X/p.Q36X

Beta-ketothiolase (MAT) Biotinidase deficiency CAH-OHase deficiency CPT II Crigler Najjar syndrome Cystinosis Cystinuria Dihydropteridine reductase deficiency Dihydrolipoyl DH (E3) Formiminoglutamatetransferase Galactosaemia (GALT) Glutaric aciduria type (GA) Glutathione-synthase deficiency Glycogen Storage Disease - all Hepatorenal Tyrosinosis type I Histidinaemia L--hydroxyglutaric aciduria Hypophosphatasia HMG-CoA Lyase Deficiency Hyperoxaluria type (AGXT) Holocarboxylase Synthase (HCSD) Isovaleric Acidaemia (IVA) Lesh Nyhan Syndrome Alkaptonuria Lysosomal Storage Disease (LSD) Methylmalonic Acidaemia (MMA) Maple Syrup Urine Disease Mitochondrial cytopathy Molybdenum Cofactor defic MPV7 Neurohepatopathy (African) MTHFR defic Multiple Acyl Dehydrogenase (MADD) Myoadenylate Deaminase Non Ketotic Hyperglycinaemia (NKH) Ornithine Amino Transferase defic Peroxisomal Acyl-CoA Oxidase Prolidase Propionic Acidaemia PKU Pyruvate dehydrogenase Pyridoxine Dependent Epilepsy VLCADD LCHADD SCOT Urea Cycle Defects X linked Ichthyosis X-ALD Zellweger spectrum At time of abstract submission 0 3 4 5 6 7 8 9 0 3 4 5 6 7 8 9 0 3 4 5 6 7 8 9 30 3 3 33 34 35 36 37 38 39

Beta-ketothiolase (MAT) Biotinidase deficiency CAH-OHase deficiency CPT II Crigler Najjar syndrome Cystinosis Cystinuria Dihydropteridine reductase deficiency Dihydrolipoyl DH (E3) Formiminoglutamatetransferase Galactosaemia (GALT) Glutaric aciduria type (GA) Glutathione-synthase deficiency Glycogen Storage Disease - all Hepatorenal Tyrosinosis type I Histidinaemia L--hydroxyglutaric aciduria Hypophosphatasia HMG-CoA Lyase Deficiency Hyperoxaluria type (AGXT) Holocarboxylase Synthase (HCSD) Isovaleric Acidaemia (IVA) Lesh Nyhan Syndrome Alkaptonuria Lysosomal Storage Disease (LSD) Methylmalonic Acidaemia (MMA) Maple Syrup Urine Disease Mitochondrial cytopathy Molybdenum Cofactor defic MPV7 Neurohepatopathy (African) MTHFR defic Multiple Acyl Dehydrogenase (MADD) Myoadenylate Deaminase Non Ketotic Hyperglycinaemia (NKH) Ornithine Amino Transferase defic Peroxisomal Acyl-CoA Oxidase Prolidase Propionic Acidaemia PKU Pyruvate dehydrogenase Pyridoxine Dependent Epilepsy VLCADD LCHADD SCOT Urea Cycle Defects X linked Ichthyosis X-ALD Zellweger spectrum This week 0 3 4 5 6 7 8 9 0 3 4 5 6 7 8 9 0 3 4 5 6 7 8 9 30 3 3 33 34 35 36 37 38 39

PRIMARY HYPEROXALURIA (N=0) 8 AGXT p.ad/p.ad AGXT:p.AD/p.S58L AGXT c.445delg/c.445delg

MTDNA CYTOPATHIES (N=46) (See Poster #P4) mtdna mutations LHON mutations 5 3 0 3 3 m.778g>a m.4484t>c m.3460g>a m.3635g>a MILS mutations LHON MILS MELAS:m.343A>G NARP/Leigh:m.8993T>C/G Multiple deletions MERRF:m.8344 Large mtdna deletions m.4459a>g m.3094t>c

OTC (N=) OTC: Exdel OTC: p.pro347leu OTC:p.Leu95Ser OTC: p.asp96thr OTC:p.Pro5Leu/- OTC: del ex5-0 OTC:p.Arg4Gly OTC:p.c.867+G>T

X-LINKED ADRENOLEUKODYSTROPHY (N=0) 3 ABCD:p.R58Q ABCD p.r58qw ABCD: p.r660p ABCD: p.g5s ABCD: p.s08l ABCD:p.P543L ABCD: p.y74c

-OH DEFICIENCY CAH (N=) CYPA: 5` convers (incl ex )/compl gene del CYPA: 5` convers (incl ex )(?Homozyg) CYPA: p.arg357trp/conv ex 4-0 CYPA: c.90-3c>g homoz CYPA: c.90-3c>g/cypa*0k CYPA:p.Ile73Asn/p.Ile73Asn CYPA: p.gln38x/exon 6 cluster CYPA: conv exon 3 / conv exon 7-8 CYPA: p.r479l/?

CONCLUSIONS Most commonly diagnosed IMDs (excl. CHT and CF): GA Cystinosis Galactosaemia MPV7 PH MtDNA cytopathies: MELAS LHON Urea cycle defects (mainly OTC) Propionic Acidaemia CAH XALD

CONCLUSIONS Most commonly diagnosed IMDs (excl. CHT and CF): GA Cystinosis Significantly amenable to treatment if diagnosed early Galactosaemia MPV7 PH MtDNA cytopathies: MELAS LHON Urea cycle defects (mainly OTC) Propionic Acidaemia CAH XALD

CONCLUSIONS Most commonly diagnosed IMDs (excl. CHT and CF): GA [] p.a93t :36 ; /5 84 newborns Cystinosis [] c.97-g>a :50 ; /0 000 newborns Significantly amenable to treatment if diagnosed early Galactosaemia [3] p.s35l :60 ; /4 400 newborns MPV7 [4] p.q36x :68 ; /8 496 newborns PH p.ad?? MtDNA cytopathies: MELAS LHON Urea cycle defects (mainly OTC) Propionic Acidaemia CAH XALD Genetics With exception of mtdna, X-linked disorders (OTC and XALD) and CAH, all have underlying mutations that are unique to South African populations [] Van der Watt et al, 00; [] Owen et al, 05; [3] Henderson et al, 00; [4] Meldau et al (currently under review)

TAKE HOME MESSAGE We should be careful in SA of using IMD incidence data from other countries or anecdotal evidence to direct how we employ limited resources in the field of rare diseases. These data increasingly support our opinion that founder mutations and not consanguinity are responsible for the large proportion of recessive IMDs that we diagnose.